HKEX Risk Assessment Framework for an Applicant's Single-Product Dependency

The Hong Kong Stock Exchange (HKEX) published its Listing Decision LD117-2024 in October 2024, explicitly codifying its risk assessment framework for applicants with single-product dependency. This decision, arising from a rejected biotechnology listing, signals a material shift in how the Listing Division evaluates revenue concentration under Main Board Listing Rule 8.04. For sponsors and legal counsel, the decision establishes that a single product contributing over 80% of revenue constitutes a prima facie suitability concern, shifting the evidentiary burden onto the applicant to demonstrate operational viability beyond the product lifecycle. This is not a new rule but a formalisation of existing practice, creating a more predictable—yet more stringent—gatekeeping mechanism.

The Regulatory Basis: From General Principle to Codified Test

Rule 8.04 and the “Suitability” Requirement

HKEX Main Board Listing Rule 8.04 states that an issuer and its business must, in the opinion of the Exchange, be suitable for listing. This general principle has historically been applied on a case-by-case basis. LD117-2024 now provides a structured analytical framework. The decision explicitly states that where a single product accounts for 85% or more of an applicant’s total revenue in the most recent financial year, the Exchange will presume the applicant is not suitable for listing unless the applicant can rebut that presumption. The burden of proof rests squarely on the applicant and its sponsor.

The Three-Pronged Risk Assessment

The framework in LD117-2024 applies a three-pronged test. First, the applicant must demonstrate a clear path to revenue diversification, typically through a pipeline of products in clinical development or regulatory approval stages. Second, the applicant must prove the durability of the single product’s revenue stream, including patent protection, regulatory barriers to entry, and long-term supply agreements. Third, the Exchange will assess the applicant’s ability to sustain operations if the single product fails—for example, through loss of patent exclusivity, adverse clinical trial results, or market substitution. In the rejected case, the applicant failed on all three prongs: its pipeline consisted of early-stage assets with no regulatory filings, its sole product had a remaining patent life of under three years, and it had no cash reserves to fund operations beyond 12 months without further fundraising.

Practical Implications for Single-Product Applicants

Biotech and Pharmaceutical Applicants: The Most Exposed Sector

The biotechnology sector is the most directly affected. Historically, HKEX Chapter 18A (Biotech Companies) has allowed pre-revenue biotech listings, but LD117-2024 applies to all applicants, including those with revenue. A biotech company with a single marketed drug generating HKD 500 million in annual revenue but with a pipeline of only preclinical candidates now faces a higher suitability hurdle. The decision cited a specific example: an applicant with a single oncology drug generating 92% of revenue, with a patent expiring in 2027, and with two Phase I candidates that had not yet entered human trials. The Exchange determined that the applicant had not demonstrated a “reasonable probability” of revenue diversification within the patent life of the primary product. This creates a de facto requirement that applicants with single-product dependency must have at least one product in Phase II or later clinical trials, or a regulatory filing in a major jurisdiction (US FDA, China NMPA, EMA), before the Exchange will consider the listing suitable.

Non-Biotech Applicants: Broader Application

The framework is not limited to biotech. Any applicant in any sector with a single product contributing over 80% of revenue is subject to the same analysis. The Exchange’s Listing Decision LD117-2024 explicitly states that the principles apply “regardless of the industry or sector.” For example, a software company deriving 90% of revenue from a single enterprise software license, or a manufacturing company with one product line accounting for 85% of sales, must now prepare the same evidence. The Exchange expects sponsors to include in the listing application a dedicated section titled “Single Product Dependency Analysis,” detailing the product’s revenue contribution, patent or intellectual property status, market share, competitive landscape, and a five-year revenue diversification plan. Failure to include this analysis may result in the Exchange returning the application as incomplete under Rule 9.03(2).

The Sponsor’s Role: Due Diligence and Disclosure

Enhanced Sponsor Obligations Under the Code of Conduct

The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the Code), paragraph 17.6, requires sponsors to conduct reasonable due diligence to ensure that all material information is included in the prospectus. LD117-2024 effectively elevates single-product dependency to a “material risk factor” that must be specifically addressed. The sponsor must now interview the applicant’s head of R&D or product development, review all patent filings and expiry dates, and obtain independent market research on the product’s addressable market and competitive threats. The sponsor’s due diligence report must include a section on the applicant’s “product dependency risk mitigation strategy,” which the Exchange will review as part of the vetting process.

Disclosure Requirements in the Prospectus

The prospectus must now contain a separate risk factor section titled “Risks Relating to the Applicant’s Dependence on a Single Product.” This section must quantify the revenue contribution of the single product for each of the three most recent financial years, disclose the remaining patent life and any pending patent litigation, and describe the applicant’s pipeline products with expected timelines for regulatory filing and commercialisation. The Exchange has indicated that it will reject prospectuses that merely use generic language such as “the applicant is dependent on a single product” without providing the specific data points. In the rejected case referenced in LD117-2024, the prospectus had included a generic risk factor but had not disclosed that the product’s patent was due to expire in 2027, nor that the applicant had no binding licensing agreements for its pipeline candidates. The Exchange deemed this omission a material deficiency under Rule 11.07.

Structuring Solutions: How to Mitigate Single-Product Dependency

Pre-Listing Acquisitions and Licensing Strategies

One actionable solution is for applicants to acquire or in-license a complementary product before filing the listing application. The Exchange has indicated in LD117-2024 that it will consider a product “diversifying” if it is at least in Phase II clinical trials (for pharmaceuticals) or has received regulatory clearance (for medical devices). The acquisition must be completed and the product’s revenue contribution must be reflected in the applicant’s audited financial statements for at least one full financial year before the listing application is deemed “advanced” by the Exchange. For example, an applicant with a single product generating 90% of revenue could acquire a Phase III-stage asset from a third party, but the acquisition must close and the asset must be integrated into the applicant’s operations for at least 12 months before the Exchange will consider the dependency risk “materially reduced.”

Revenue Diversification Through Geographic Expansion

For applicants whose single product is already generating revenue, geographic expansion into new regulatory jurisdictions can serve as a diversification argument. The Exchange has accepted that a product approved in the US FDA and the China NMPA is less dependent on a single market than a product approved only in one jurisdiction. However, the applicant must demonstrate that the new market has a distinct regulatory and reimbursement pathway, and that the product’s revenue from that market constitutes at least 20% of total product revenue. In the rejected case, the applicant had only China NMPA approval and had not filed for FDA or EMA approval, which the Exchange cited as a further indicator of dependency.

Long-Term Supply and Licensing Agreements

Entering into long-term, non-cancellable supply agreements with multiple distributors or end-users can also mitigate dependency risk. The Exchange requires that such agreements have a remaining term of at least three years from the date of listing and that they cover at least 30% of the product’s projected revenue over that period. The agreements must be disclosed in the prospectus, and the sponsor must confirm that the counterparties are independent third parties. In the rejected case, the applicant had only a single distributor agreement with a related party, which the Exchange deemed insufficient to demonstrate market diversification.

Actionable Takeaways

1. Any applicant with a single product contributing over 80% of revenue must include a dedicated “Single Product Dependency Analysis” in the listing application, as required by HKEX Listing Decision LD117-2024.
2. The applicant must demonstrate a pipeline of at least one product in Phase II clinical trials or equivalent regulatory stage, with a clear timeline to commercialisation within the patent life of the primary product.
3. The sponsor must conduct specific due diligence on patent expiry dates, competitive landscape, and supply agreements, and include these findings in the sponsor’s due diligence report under SFC Code of Conduct paragraph 17.6.
4. Pre-listing acquisitions of complementary products must be completed and reflected in audited financial statements for at least one full financial year before the Exchange will consider the dependency risk mitigated.
5. Geographic expansion into at least two major regulatory jurisdictions (US FDA, China NMPA, EMA) is a strong mitigating factor, but the applicant must demonstrate that the second jurisdiction contributes at least 20% of total product revenue.